Only in Titles

Search results for: Recombinant Human tPA PLAT Proteins

paperclip

#30597502   2018/12/31 To Up

tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.

Recombinant tissue-type plasminogen activator (r-tPA) was approved by U.S. Food and Drug Administration as a thrombolytic drug. However, a high dose of r-tPA (up to 100 mg/person) is typically used in clinical applications. Such high dosage leads to severe side effects including haemorrhage and neurotoxicity, which can be fatal. To improve the proteolytic properties of tPA to enhance thrombolytic therapy, we designed a series of mutants in tPA serine protease domain (tPA-SPD) based on the crystal structure of tPA-SPD:plasminogen activators inhibitor-1 (PAI-1) complex that we determined recently. We found that the A146Y substitution in tPA-SPD(A146Y) enhanced resistance to PAI-1 inactivation by 30-fold compared with original tPA-SPD. Interestingly, the tPA-SPD(A146Y) variant showed fivefold higher activation for plasminogen compared with tPA-SPD. The variant also demonstrated thrombolytic activity stronger than tPA-SPD in a clot lysis assay. In vivo, we showed tPA-SPD(A146Y) possessed higher thrombolytic efficacy in a pulmonary embolism model compared with original tPA-SPD. Furthermore, a mouse tail bleeding assay showed that tPA-SPD(A146Y) did not increase bleeding risk compared with clinical drug r-tPA. Together, our findings reveal novel functions of A146Y variant, which not only increases the catalytic efficiency of the enzyme, but also enhances resistance to PAI-1 inhibition, and demonstrating that tPA-SPD (A146Y) variant is a much improved agent for thrombolytic therapy.
Shuangzhou Peng, Guangpu Xue, Shanli Chen, Zhuo Chen, Cai Yuan, Jinyu Li, Mingdong Huang

2631 related Products with: tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.

100ul100ug100ul 100ul100Tests48 assays 100ug Lyophilized100ul100μl 100ul100ul100ug Lyophilized

Related Pathways

paperclip

#30522372   2018/12/06 To Up

Production of human tissue-type plasminogen activator (htPA) using cultured transgenic pig mammary gland cells.

Tissue plasminogen activator (tPA) is a protein involved in the breakdown of blood clots. We have previously produced a human tPA (htPA)-overexpressing transgenic pig using a mammary gland-specific promoter. In this study, we have established a transgenic pig mammary gland cell line that produces recombinant htPA. The mammary gland cells grew well and retained their character over long periods of culture. There was no difference in the extent of apoptosis in transgenic cells compared to wild-type mammary gland cells. In addition, the transgenic mammary gland cells expressed and secreted htPA into the conditioned media at a concentration similar to that in milk. This transgenic cell line represents a simple and ethical method for recombinant htPA production.
Hak-Jae Chung, Hyun-Jung Park, Sun-Young Baek, Jin-Ki Park, Won-Young Lee, Kyung-Woon Kim, Yu-Mi Jo, Shinichi Hochi, Yong-Min Kim, Tae-Jeong Choi, Eun-Suek Cho, Kyu-Ho Cho

1997 related Products with: Production of human tissue-type plasminogen activator (htPA) using cultured transgenic pig mammary gland cells.

200 96 Tests/kit200 1mg0.1mg1.00 flask96T100.00 ug100 extractions200

Related Pathways

paperclip

#27522496   2016/08/10 To Up

Use of tissue plasminogen activator in the treatment of shunt blockage secondary to intraventricular haemorrhage.

A 51-year-old woman with a history of idiopathic aqueduct stenosis, treated initially with insertion of a ventriculo peritoneal shunt, presented to our institution with shunt dysfunction. She had previously undergone multiple shunt revisions for shunt infection, shunt blockage and low-pressure symptoms, most recently with conversion to a ventriculo atrial (VA) shunt. Her VA shunt was again revised, with replacement of the ventricular catheter, however surgery was complicated by a large intraventricular haemorrhage (IVH) requiring placement of an external ventricular drain (EVD). Prior to eventual removal of her EVD it was determined that the VA shunt had blocked as a result of the IVH. Subsequently alteplase, a recombinant tissue plasminogen activator (tPA), was administered into the shunt reservoir, resulting in successful return of shunt function, therefore avoiding the need for further shunt revision. This is the first description of the use of tPA to unblock a shunt obstructed by blood.
J Jones, P Schweder, K J Drummond, A H Kaye

2273 related Products with: Use of tissue plasminogen activator in the treatment of shunt blockage secondary to intraventricular haemorrhage.

96 wells200 200 96 Tests/kit1mg

Related Pathways

paperclip

#27359348   2016/08/17 To Up

Thrombolysis by chemically modified coagulation factor Xa.

Essentials Factor Xa (FXa) acquires cleavage-mediated tissue plasminogen activator (tPA) cofactor activity. Recombinant (r) tPA is the predominant thrombolytic drug, but it may cause systemic side effects. Chemically modified, non-enzymatic FXa was produced (Xai-K), which rapidly lysed thrombi in mice. Unlike rtPA, Xai-K had no systemic fibrinolysis activation markers, indicating improved safety.
E L G Pryzdial, S C Meixner, K Talbot, L J Eltringham-Smith, J R Baylis, F M H Lee, C J Kastrup, W P Sheffield

1601 related Products with: Thrombolysis by chemically modified coagulation factor Xa.

2 1mgOne 96-Well Strip Micropl20 IU0.5mg100.00 ug0.25mg100.00 ug0.1 mg100.00 ug50 IU0.1mg

Related Pathways

paperclip

#26626577   2015/11/25 To Up

The story of an exceptional serine protease, tissue-type plasminogen activator (tPA).

The only acute treatment of ischemic stroke approved by the health authorities is tissue recombinant plasminogen activator (tPA)-induced thrombolysis. Under physiological conditions, tPA, belonging to the serine protease family, is secreted by endothelial and brain cells (neurons, astrocytes, microglia, oligodendrocytes). Although revascularisation induced by tPA is beneficial during a stroke, research over the past 20 years shows that tPA can also be deleterious for the brain parenchyma. Thus, in this review of the literature, after a brief history on the discovery of tPA, we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions.
M Hébert, F Lesept, D Vivien, R Macrez

3000 related Products with: The story of an exceptional serine protease, tissue-type plasminogen activator (tPA).

96 Tests/kit200 200 200 100.00 ug0.1ml (1mg/ml)1mg0.1ml (1mg/ml)

Related Pathways

paperclip

#26419527   2015/09/26 To Up

Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Protocol deviations before and after tissue plasminogen activator (tPA) treatment for ischemic stroke are common. It is unclear if patient or hospital factors predict protocol deviations. We examined predictors of protocol deviations and the effects of protocol violations on symptomatic intracerebral hemorrhage (sICH).
Eric E Adelman, Phillip A Scott, Lesli E Skolarus, Allison K Fox, Shirley M Frederiksen, William J Meurer

1202 related Products with: Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

96 Tests/kit200 1mg0.1mg200 200

Related Pathways

paperclip

#26091403   // To Up

The Naïve Murine Cornea as a Model System to Identify Novel Endogenous Regulators of Lymphangiogenesis: TRAIL and rtPA.

In the murine cornea, which is an established model for analyzing pathologic lymphatic vessel growth, phenotypic heterogeneity of the endogenous lymphatic vessels in the limbus of the cornea was previously described. In this study, the cornea of BALB/c, C57BL/6, and FVB mice with different limbal lymphangiogenic phenotypes was analyzed to identify novel candidates potentially influencing lymphatic vessel growth.
Birgit Regenfuß, Marie-Luise Dreisow, Deniz Hos, Sharmila Masli, Felix Bock, Claus Cursiefen

2514 related Products with: The Naïve Murine Cornea as a Model System to Identify Novel Endogenous Regulators of Lymphangiogenesis: TRAIL and rtPA.

430 tests1 kit(96 Wells)100 assays1 kit(96 Wells)1 kit1 kit(96 Wells)100 assays

Related Pathways

paperclip

#25855589   2015/04/09 To Up

Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.

Recombinant tissue-type plasminogen activator (tPA, trade name Alteplase), currently the only drug approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of cerebral ischaemic stroke, has been implicated in a number of adverse effects reportedly mediated by interactions with the low-density lipoprotein (LDL) family receptors, including neuronal cell death and an increased risk of cerebral haemorrhage. The tissue-type plasminogen activator is the principal initiator of thrombolysis in human physiology, an effect that is mediated directly via localised activation of the plasmin zymogen plasminogen at the surface of fibrin clots in the vascular lumen. Here, we sought to identify a ligand to tPA capable of inhibiting the relevant LDL family receptors without interfering with the fibrinolytic activity of tPA. Systematic evolution of ligands by exponential enrichment (SELEX) was employed to isolate tPA-binding RNA aptamers, which were characterised in biochemical assays of tPA association to low density lipoprotein receptor-related protein-1 (LRP-1, an LDL receptor family member); tPA-mediated in vitro and ex vivo clot lysis; and tPA-mediated plasminogen activation in the absence and presence of a stimulating soluble fibrin fragment. Two aptamers, K18 and K32, had minimal effects on clot lysis, but were able to efficiently inhibit tPA-LRP-1 association and LDL receptor family-mediated endocytosis in human vascular endothelial cells and astrocytes. These observations suggest that coadministration alongside tPA may be a viable strategy to improve the safety of thrombolytic treatment of cerebral ischaemic stroke by restricting tPA activity to the vascular lumen.
Nils Bjerregaard, Kenneth A Bøtkjær, Nicky Helsen, Peter A Andreasen, Daniel M Dupont

2963 related Products with: Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.

100.00 ug96 Tests/kit1mg200 0.1mg200

Related Pathways

paperclip

#24764453   2014/04/24 To Up

Tissue plasminogen activator promotes postischemic neutrophil recruitment via its proteolytic and nonproteolytic properties.

Neutrophil infiltration of the postischemic tissue considerably contributes to organ dysfunction on ischemia/reperfusion injury. Beyond its established role in fibrinolysis, tissue-type plasminogen activator (tPA) has recently been implicated in nonfibrinolytic processes. The role of this serine protease in the recruitment process of neutrophils remains largely obscure.
Bernd Uhl, Gabriele Zuchtriegel, Daniel Puhr-Westerheide, Marc Praetner, Markus Rehberg, Matthias Fabritius, Maximilian Hessenauer, Martin Holzer, Andrej Khandoga, Robert Fürst, Stefan Zahler, Fritz Krombach, Christoph A Reichel

1091 related Products with: Tissue plasminogen activator promotes postischemic neutrophil recruitment via its proteolytic and nonproteolytic properties.

200 96 Tests/kit1mg200 0.1mg200 100.00 ug1000pcs

Related Pathways

paperclip

#24176900   2013/12/03 To Up

Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model.
Rosana Gerometta, Sandeep Kumar, Shaily Shah, Larry Alvarez, Oscar Candia, John Danias

2401 related Products with: Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

200 200 1mg0.1mg96 Tests/kit200

Related Pathways